Elixinol Wellness Limited (ASX:EXL) has filed an Appendix 3B disclosing a proposed issue of up to 666,666,666 ordinary fully paid shares as deferred non-cash consideration payable to the vendor for the acquisition of Vitable, with a proposed issue date of 7 December 2026.

Key Points

  • Up to 666,666,666 EXL ordinary fully paid shares proposed to be issued as deferred non-cash consideration for the Vitable acquisition
  • Shares to be issued in five tranches with an estimated total AUD equivalent consideration of $2,500,000, plus up to $1,000,000 in additional consideration shares subject to a market capitalisation condition
  • Shares will be issued at a floor price of $0.00525 per share
  • Security holder approval required by 27 November 2026, with a proposed issue date of 7 December 2026
  • The company has applied to ASX for a waiver of Listing Rule 7.3.4 to permit issue of shares in separate tranches, with certain tranches to be issued more than three months after the shareholder meeting date

Deferred Consideration Share Structure and Tranches

According to the filing, 476,190,476 ordinary fully paid shares will form the core deferred consideration, structured across five tranches. Tranche 1 comprises $312,500 on completion, and Tranche 2 comprises $312,500 six months after completion. Tranche 3 comprises $625,000 twelve months after completion. Tranche 4 provides up to $625,000 based on 12-month performance, split 50% on Net Revenue and 50% on Direct EBITDA, with Net Revenue of $6.0 million to $7.0 million and Direct EBITDA of nil to $700,000, calculated on a pro-rata basis. Tranche 5 provides up to $625,000 based on performance over the 12-month period ending 24 months after completion, with Net Revenue of $7.0 million to $10.0 million and Direct EBITDA of $700,000 to $1.2 million, pro rata.

Additional Market Capitalisation-Linked Consideration Shares

The filing discloses a further 190,476,190 ordinary fully paid shares, representing up to $1,000,000 in additional consideration. These shares are issuable if, within 36 months after completion, the 20-trading-day volume weighted average price (VWAP)-implied market capitalisation of EXL exceeds $20.0 million. The filing states that the number of shares issued will be calculated by reference to the applicable 20-trading-day VWAP at the relevant test date, subject to the acquisition agreement, applicable law, ASX requirements, and any ASX waiver. All shares in the proposed issue are existing class securities and will rank equally in all respects from their issue date with existing issued securities in that class.

Conditions, ASX Waiver Application and Timetable

The proposed issue is subject to security holder approval, with 27 November 2026 disclosed as the estimated date for determination. The company has applied to ASX for a waiver of Listing Rule 7.3.4 to permit the shares comprising the deferred consideration to be issued in separate tranches, including certain tranches to be issued more than three months after the date of the shareholder meeting approving the issue. The filing states that if the waiver is not granted, the company will consider whether the relevant deferred consideration shares can instead be issued within the period permitted under Listing Rule 7.3.4. The proposed issue date is 7 December 2026. All shares are to be issued at the floor price of $0.00525 per share.